دورية أكاديمية

Muscle stimulation in advanced idiopathic pulmonary fibrosis: a randomised placebo-controlled feasibility study.

التفاصيل البيبلوغرافية
العنوان: Muscle stimulation in advanced idiopathic pulmonary fibrosis: a randomised placebo-controlled feasibility study.
المؤلفون: Nolan, CM, Patel, S, Barker, RE, Walsh, JA, Polgar, O, Maddocks, M, George, PM, Renzoni, EA, Wells, AU, Molyneaux, PL, Kouranos, V, Chua, F, Maher, TM, Man, WD-C
المساهمون: National Institute for Health Research, British Lung Foundation
المصدر: 11 ; 1
بيانات النشر: BMJ Journals
سنة النشر: 2021
المجموعة: Imperial College London: Spiral
مصطلحات موضوعية: interstitial lung disease, rehabilitation medicine, respiratory medicine (see thoracic medicine), Aged, Double-Blind Method, Feasibility Studies, Humans, Idiopathic Pulmonary Fibrosis, Quadriceps Muscle, Walk Test, 1103 Clinical Sciences, 1117 Public Health and Health Services, 1199 Other Medical and Health Sciences
جغرافية الموضوع: England
الوصف: OBJECTIVES: To assess the acceptability of neuromuscular electrical stimulation (NMES) of the quadriceps muscles in people with idiopathic pulmonary fibrosis (IPF) and to identify whether a future definitive trial is feasible. DESIGN: A randomised, parallel, two-group, participant and assessor-blinded, placebo-controlled feasibility trial with embedded qualitative interviews. SETTING: Outpatient department, Royal Brompton and Harefield Hospitals. PARTICIPANTS: Twenty-two people with IPF: median (25th, 75th centiles) age 76 (74, 82) years, forced vital capacity 62 (50, 75) % predicted, 6 min walk test distance 289 (149, 360) m. INTERVENTIONS: Usual care (home-based exercise, weekly telephone support, breathlessness management leaflet) with either placebo or active NMES for 6 weeks, with follow-up at 6 and 12 weeks. PRIMARY OUTCOME MEASURES: Feasibility of recruitment and retention, treatment uptake and adherence, outcome assessments, participant and outcome assessor blinding and adverse events related to interventions. SECONDARY OUTCOME MEASURES: Outcome measures with potential to be primary or secondary outcomes in a definitive clinical trial. In addition, purposively sampled participants were interviewed to capture their experiences and acceptability of the trial. RESULTS: Out of 364 people screened, 23 were recruited: 11 were allocated to each group and one was withdrawn prior to randomisation. Compared with the control group, a greater proportion of the intervention group completed the intervention, remained in the trial blinded to group allocation and experienced intervention-related adverse events. Assessor blinding was maintained. The secondary outcome measures were feasible with most missing data associated with the accelerometer. Small participant numbers precluded identification of an outcome measure suitable for a definitive trial. Qualitative findings demonstrated that trial process and active NMES were acceptable but there were concerns about the credibility of placebo NMES. CONCLUSIONS: Primarily ...
نوع الوثيقة: article in journal/newspaper
اللغة: English
تدمد: 2044-6055
العلاقة: BMJ Open; http://hdl.handle.net/10044/1/90345Test; CS-2013-13-017; C17-3
DOI: 10.1136/bmjopen-2021-048808
الإتاحة: https://doi.org/10.1136/bmjopen-2021-048808Test
http://hdl.handle.net/10044/1/90345Test
حقوق: © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0Test/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0Test/. ; http://creativecommons.org/licenses/by-nc/4.0Test/
رقم الانضمام: edsbas.2C0ABD5
قاعدة البيانات: BASE
الوصف
تدمد:20446055
DOI:10.1136/bmjopen-2021-048808